Condition: ER-Positive HER2-Negative Breast Cancer · Sponsor: AstraZeneca
The purpose of this study is to investigate the efficacy, safety, and tolerability of camizestrant in combination with ribociclib in patients with ER+ HER2- BC who have not received any other systemic treatment for advanced disease. Participants will be treated within the trial until they discontinue the study treatment for any reason.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Duarte, California, United States | Not Yet Recruiting |
| Research Site | Palo Alto, California, United States | Not Yet Recruiting |
| Research Site | Marietta, Georgia, United States | Not Yet Recruiting |
| Research Site | Evanston, Illinois, United States | Not Yet Recruiting |
| Research Site | Edgewood, Kentucky, United States | Not Yet Recruiting |
| Research Site | Louisville, Kentucky, United States | Not Yet Recruiting |
| Research Site | Reno, Nevada, United States | Not Yet Recruiting |
| Research Site | Sioux Falls, South Dakota, United States | Not Yet Recruiting |
| Research Site | Nashville, Tennessee, United States | Not Yet Recruiting |
| Research Site | Fort Worth, Texas, United States | Not Yet Recruiting |
| Research Site | Kingwood, Texas, United States | Recruiting |
| Research Site | Midlothian, Virginia, United States | Not Yet Recruiting |
+ 72 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07647328